AOD-9604 in Ban Na — Fat Loss Peptide Research Guide
AOD-9604 research guide for Ban Na. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
For anyone in Ban Na searching for AOD-9604, the foundational reality is that this compound is available only through an online research supply market. The benefit of this online-only market is that serious vendors are judged entirely by their analytical documentation, giving researchers better verification tools than any physical store could provide. Vendors worth sourcing from make readily available batch-matched Certificates of Analysis showing HPLC purity analysis, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the precise product run you are purchasing. The sections below cover what Ban Na researchers need to know about sourcing, verifying, and handling AOD-9604 for scientific research use.
Understanding AOD-9604 — Biology & Evidence
AOD-9604 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Ban Na studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
Where to Buy AOD-9604 — A Researcher's Guide
The first step for any Ban Na researcher sourcing AOD-9604 is identifying 2-3 vendors with documented positive community reputations — search results alone are too heavily influenced by marketing spend. A COA for AOD-9604 should include: HPLC purity percentage with the full chromatographic trace, mass spectrometry data confirming the correct molecular weight, endotoxin test results, and a residual solvent panel — all batch-matched. For Ban Na researchers evaluating new suppliers: a test quantity before committing to research volumes before placing larger orders is what experienced peptide researchers consistently do. For Ban Na researchers making a first AOD-9604 purchase: work through this evaluation framework first, start with a modest quantity, and verify batch traceability on arrival before use.
Order AOD-9604 — ships to Ban Na
COA-verified · International tracking · Research grade
AOD-9604 is sold for research purposes only and is not approved for human consumption by the FDA or equivalent agencies worldwide — all information here is provided for educational purposes. Reconstitute AOD-9604 with bacteriostatic water at an appropriate concentration for your protocol; a standard 5mg reconstituted in 2mL produces 2.5mg/mL — providing 25mcg per unit measured on a 100-unit syringe. Bacterial endotoxin contamination is the greatest safety hazard specific to research peptides — verify endotoxin testing is included in the batch-specific COA before any injectable research application. Protocol documentation — documenting product details, dates, and administration precisely — is a sound practice for any AOD-9604 protocol that ensures unusual findings can be explained.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
